A Phase I, Dose-Escalation Study Of Adg106, A Fully Human Anti-Cd137 Agonistic Antibody, In Subjects With Advanced Solid Tumors Or Relapsed/Refractory Non-Hodgkin Lymphoma.
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要